Skin Squamous Cell Carcinoma

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Skin Squamous Cell Carcinoma is an early-stage landscape with 4 programs across 2 companies. The most active players are EMD Serono, Teva.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

EMD Serono

1 program

Phase 2

Teva

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Paclitaxel

Teva

Phase 11

Natural Killer Cell Therapy

M.D. Anderson Cancer Center

Phase 22

Avelumab

EMD Serono

Erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

5programs

Small molecule240%

Cell therapy240%

Monoclonal antibody120%

Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01198028·42 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)